Go Pro
NASDAQ:BOLD

Boundless Bio Q4 2024 Earnings Report

Boundless Bio logo
$2.78 0.00 (0.00%)
As of 10:47 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Boundless Bio EPS Results

Actual EPS
-$0.74
Consensus EPS
-$0.74
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Boundless Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Boundless Bio Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 27, 2025
Conference Call Time
7:00AM ET

Boundless Bio Earnings Headlines

The world’s least risky AI stock?
Whitney Tilson, senior editor at Stansberry Research, has identified a company he calls the world's safest AI stock, one most investors have never heard of. The firm sits at the intersection of AI, energy, and defense, and one of America's most famous investors reportedly put roughly half his fund into it. In recent years it has returned more than Apple, Amazon, and the S&P 500 combined. Tilson has released a free presentation naming the company and its ticker symbol, no payment or email required.tc pixel
See More Boundless Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Boundless Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Boundless Bio and other key companies, straight to your email.

About Boundless Bio

Boundless Bio (NASDAQ:BOLD) Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

View Boundless Bio Profile